Abbott Laboratories (ABT) 48.35 $ABT Abbott Labs' Q1

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Abbott Laboratories (ABT) 48.35 $ABT

Abbott Labs' Q1 beats views
at Investor's Business Daily - 39 mins ago
The medical-products giant reported EPS of 47 cents, up 12%, on sales of $4.9 bil, up 3%, with both results above analyst expectations. Abbott Laboratories (ABT) affirmed its full-year EPS guidance of $2.10$2.20. Leerink analyst Danielle Antalffy...
ABT: 48.35 (+1.23)

Abbott Laboratories (ABT) Stock Gained Today on Strong Earnings Beat
at The Street - 2 hrs 6 mins ago
Abbott Laboratories (ABT) shares rose after the company beat analysts' first quarter earnings and revenue expectations today.
ABT: 48.35 (+1.23)

Omnicare reportedly exploring sale; trading halted
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 2:33PM CDT

ABT: 48.35 (+1.23), OCR: 84.52 (+3.45)

Abbott Laboratories' (ABT) CEO Miles White on Q1 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Apr 22, 1:26PM CDT

ABT: 48.35 (+1.23)

Abbott Labs (ABT) Beats on Q1 Earnings, View Reiterated - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 22, 12:18PM CDT
Abbott Laboratories (ABT) reported first-quarter 2015 earnings of 47 cents per share, up 38.2% from the year-ago quarter and beat the Zacks Consensus Estimate of 42 cents.
ABT: 48.35 (+1.23), VRX: 206.93 (-3.92), SHPG: 253.58 (+3.70), MYL: 72.40 (-1.67)

How to Trade the Market's Most-Active Stocks
at The Street - Wed Apr 22, 12:02PM CDT
Keep these stocks on your trading radar.
ABT: 48.35 (+1.23), MCD: 97.84 (+2.97), EMC: 27.13 (+0.81), BABA: 82.05 (-0.37)

Abbott Laboratories (ABT) Earnings Report: Q1 2015 Conference Call Transcript
at The Street - Wed Apr 22, 11:53AM CDT
The following Abbott Laboratories (ABT) conference call took place on April 22, 2015, 09:00 AM ET. This is a transcript of that earnings call:
ABT: 48.35 (+1.23)

St. Jude, Abbott Labs Beat Q1 Expectations
at Investor's Business Daily - Wed Apr 22, 9:54AM CDT
Two medical-product giants were rising in the stock market early Wednesday after beating first-quarter expectations. St. Jude Medical (STJ) jumped 6.5% to a new high above 73 after it reported earnings of 91 cents a share, up 6% from the year-earlier...
ABT: 48.35 (+1.23), STJ: 73.55 (+4.43), ABBV: 64.52 (+0.91)

Today's Unusual Social Activity Stock: Abbott Laboratories (ABT)
at The Street - Wed Apr 22, 8:48AM CDT
Trade-Ideas LLC identified Abbott Laboratories (ABT) as an unusual social activity candidate
ABT: 48.35 (+1.23)

Abbott Labs (ABT) Beats On Earnings in Q1 - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 22, 8:22AM CDT
Abbott Labs (ABT) Beats On Earnings in Q1
ABT: 48.35 (+1.23)

Abbott Laboratories (ABT) Q1 2015 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Wed Apr 22, 7:55AM CDT

ABT: 48.35 (+1.23)

Gilead Sciences Vs. AbbVie: Which Is A Better Buy?
Mycroft - at Seeking Alpha - Wed Apr 22, 7:49AM CDT

JNJ: 100.43 (+0.13), ABT: 48.35 (+1.23), PCYC: 256.98 (-0.77), GILD: 104.18 (-1.02), SHPG: 253.58 (+3.70), ABBV: 64.52 (+0.91)

Abbott Q1 revenues off 7%; EPS up 529%; guidance maintained
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 7:31AM CDT

ABT: 48.35 (+1.23)

Abbott beats Street 1Q forecasts
Automated Insights - Wed Apr 22, 6:57AM CDT
ABBOTT PARK, Ill. (AP) _ Abbott Laboratories (ABT) on Wednesday reported first-quarter net income of $2.29 billion.
ABT: 48.35 (+1.23)

Abbott Laboratories beats by $0.05, beats on revenue
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 6:50AM CDT

ABT: 48.35 (+1.23)

Abbott Reports First-Quarter 2015 Results
PR Newswire - Wed Apr 22, 6:45AM CDT
Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2015.
ABT: 48.35 (+1.23)

Notable earnings before Wednesday's open
Seeking Alpha - at Seeking Alpha - Tue Apr 21, 4:30PM CDT

DHI: 27.03 (-1.53), MKTX: 88.66 (-1.35), NLSN: 46.10 (+0.27), SEIC: 45.99 (+0.68), AZZ: 46.11 (-0.02), HBAN: 11.03 (-0.14), TDY: 109.69 (+0.48), PCH: 37.47 (-0.65), WERN: 30.29 (-1.11), NS: 65.49 (+1.78), BABY: 41.64 (+1.71), APH: 56.81 (-1.35), TEL: 70.14 (+0.13), R: 97.95 (+1.15), ANGI: 6.46 (+0.31), EVR: 50.80 (+1.28), CFG: 25.49 (+0.45), SIX: 49.97 (+1.37), EMC: 27.13 (+0.81), OC: 42.28 (-0.61), WAB: 98.61 (+2.84), BK: 42.43 (+1.39), KO: 41.31 (+0.53), LAD: 102.54 (+0.04), ABT: 48.35 (+1.23), TMO: 130.69 (-3.75), TROW: 82.59 (-0.21), SONS: 7.89 (+0.05), ALV: 120.22 (-3.47), GNTX: 18.26 (+0.09), BA: 151.19 (-2.14), TUP: 67.25 (-2.60), KNX: 32.62 (+0.07), STJ: 73.55 (+4.43), MCD: 97.84 (+2.97), AN: 65.83 (+0.93)

Abbott Laboratories Set to Possibly Pullback After Yesterday's Rally of 1.05%
Comtex SmarTrend(R) - Tue Apr 21, 4:10PM CDT
Abbott Laboratories (NYSE:ABT) traded in a range yesterday that spanned from a low of $46.72 to a high of $47.28. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $46.89 on volume of 8.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ABT: 48.35 (+1.23)

Abbott Laboratories (ABT) Stock Advances Today Ahead of Wednesday's Earnings Release
at The Street - Tue Apr 21, 12:42PM CDT
Abbott Laboratories (ABT) shares are gaining today ahead of the release of the company's earnings results tomorrow morning before the market opens.
ABT: 48.35 (+1.23)

Abbott Laboratories (ABT) Crosses Pivot Point Resistance at $46.77
Comtex SmarTrend(R) - Tue Apr 21, 9:35AM CDT
Shares of Abbott Laboratories (NYSE:ABT) opened today above their pivot of $46.57 and have already reached the first level of resistance at $46.77. Should the shares continue to rise, the resistance pivots of $46.91 and $47.25 will be of interest.
ABT: 48.35 (+1.23)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Master Sommeliers and Italian Producers Clash on Wine Lists

Updated Category News Views 166

Wines Jockeying for New York’s Coveted Lists Alright, picture a stage set up in New York City like an arena. But instead of gladiators, you've got master sommeliers on one side and Italian wine producers on the other, each armed with their own arguments. They're locked in a battle over what it really takes to get a bottle imbedded on a New York City's prestigious wine...

Continue Reading
Apalutamide Boosts Outlook for Prostate Cancer Treatment

Updated Category News Views 98

Fresh Findings on High-Risk Prostate Cancer Treatments In an industry that often feels like a game of chess, Johnson & Johnson's recent news unveils another one of their strategic moves with the announcement of breakthrough results from their Phase 3 PROTEUS substudy. Turns out, ERLEADA®, their apalutamide treatment, isn't just another pawn; it's a potential...

Continue Reading
Aluminum Design Fumble: Geometry Over Wall Thickness

Updated Category News Views 218

A Misstep in Aluminum Design Practices Well, here's a nugget of wisdom for the metal enthusiasts out there—stop beefing up aluminum components with thicker walls and focus on smart geometry. This isn't a drill, folks. Mark Coyle, a seasoned mind over at American Custom Metals, has been waving the flag for smarter aluminum design methods right from Rochester, NY, and...

Continue Reading
CSTS Unveils PremierX in NYC: A Bold Entertainment Move

Updated Category News Views 270

Welcome to the New Era of Entertainment Out of the blockbusters and into the open air, eh? On October 30, 2026, CSTS Enterprises flipped the New York skyline into a canvas for their grand kickoff of PremierXTM—a live entertainment brand poised to redefine how we gobble up our music, sport, and art. Now, there's a shot of adrenaline New Yorkers weren't exactly begging...

Continue Reading
Swanson Nexus Pro Launch: Boost for Dietitians

Updated Category News Views 213

Swanson Enters the Education Arena for Nutritionists Swanson Vitamins is mixing things up again! This time, they're launching something called Swanson Vitamins Nexus Pro, aimed squarely at the registered dietitians and licensed nutritionists crowd. Starting out as the place to grab your basic vitamins, Swanson's not resting on their supplement laurels. No, siree. They've...

Continue Reading
Alaska's Insurance Maze: Coverage Over Cheap Policies

Updated Category News Views 171

Beyond Premiums: Assessing Real Coverage Needs The Alaskan wilderness isn't just home to stunning views; it's also a land where insurance needs to go beyond the average cookie-cutter policy. You'd think the cheapest option would suffice, but that's where residents might trip into financial quicksand. Devery Prince, a seasoned insurance principal, sheds light on why...

Continue Reading
Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 145

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Updated Category News Views 106

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Continue Reading
Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Updated Category News Views 48

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

Continue Reading
Love Business Group Helps SMEs Navigate Broadband Choices

Updated Category News Views 0

Understanding Broadband Needs for UK SMEs When you're knee-deep in running a small biz in the UK, sorting out your broadband needs can feel like sifting through a thousand-piece puzzle. Enter Love Business Group, getting a nod of recognition for being the SME knight in shining armor. Aimed at businesses of all sizes, they've been pegged by Expert Consumers for helping...

Continue Reading

Top 5 Most Recently Viewed Articles

VENU Embraces Blockchain: A New Era for Live Events

Updated Category News Views 203

VENU's Groundbreaking Blockchain Initiative in Live Entertainment In a significant move that signals the future of live entertainment, VENU (NYSE American: VENU), a leading operator of premium venues across the country, has announced an innovative blockchain-powered platform set to launch in 2026. This strategy is revolutionary, intending to blend physical experiences...

Continue Reading
Empowering Leadership Transitions at Ora Enhance Customer Focus

Updated Category News Views 144

Empowering Strategic Leadership at Ora Ora, an esteemed player in the field of ophthalmic contract research organizations (CROs), has recently appointed Cindy Markham as its new Chief Commercial Officer. This strategic move underscores Ora's dedication to enhancing the customer experience, setting a new benchmark in the ophthalmic research sector. Commitment to Customer...

Continue Reading
Real Matters Announces Online Annual General Meeting Details

Updated Category News Views 166

Virtual Annual General Meeting Scheduled for Shareholders Real Matters Inc., a prominent network management services provider, has announced the date for its upcoming Annual General Meeting (AGM). The meeting is set to take place on a Thursday morning, providing a convenient option for shareholders to participate from the comfort of their homes. Accessing the AGM Online...

Continue Reading
Trinity Biotech Triumphs in Nasdaq Compliance Journey

Updated Category News Views 41

Trinity Biotech Celebrates Nasdaq Compliance Achievement Trinity Biotech plc (Nasdaq Global Select: TRIB), a leading name in biotechnology focused on human diagnostics and diabetes management solutions, including innovative wearable biosensors, has reached a significant milestone. The company recently announced it has regained compliance with the minimum market value of...

Continue Reading
Vaycaychella Transitions to Great Estate Blockchains Inc

Updated Category News Views 176

Vaycaychella Unveils a Bold New Identity Vaycaychella, Inc. (OTC Pink: VAYK) has officially announced a name change to "Great Estate Blockchains Inc." This transition signifies a rejuvenated focus on enhancing the value of historic landmarks through innovative cryptocurrency strategies. The company aims to tap into a colossal market, potentially valued in the hundreds of...

Continue Reading